Keywords: broker, assesses, ares-serono, results, analysts, goldman, sachs
Broker Assesses Ares-Serono Results
Article | 21 April 1998
Analysts at Goldman Sachs have revised downward their sales estimatesfor Swiss drugmaker Ares-Serono, following the company's first-quarter 1997 results (Marketletter April 20). ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Australia's pharma industry applauds R&D regulatory reform
